Screener
Oruka Therapeutics, Inc. ORKA Issuance of warrants
Issuance of warrants at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued.
The source filing: Oruka Therapeutics, Inc.’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 4:03 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-026929
| Line item | Series A Convertible Preferred Stock / Shares | Series A Convertible Preferred Stock / Amount | Series A Non-Voting Convertible Preferred Stock / Shares | Series A Non-Voting Convertible Preferred Stock / Amount | Series B Non-Voting Convertible Preferred Stock / Shares | Series B Non-Voting Convertible Preferred Stock / Amount | Common Stock / Shares | Common Stock / Amount | Additional Paid-In / Capital | Accumulated Other Comprehensive / Income (Loss) | Accumulated / Deficit | Total Stockholders’ / Equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Issuance costs of 2024 PIPE Financing | — | — | — | (3,263) | — | — | — | — | (8,592) | — | — | (8,592) |
| Conversion of Series A non-voting convertible preferred stock to common stock | — | — | (2,439) | (52,834) | — | — | 2,439,000 | 2 | 52,832 | — | — | 52,834 |
| Issuance of common stock under employee stock purchase plan | — | — | — | — | — | — | 2,960 | — | 53 | — | — | 53 |
| Reclassification of the Paruka warrant from liability to equity | — | — | — | — | — | — | — | — | 10,357 | — | — | 10,357 |
| Stock-based compensation expense | — | — | — | — | — | — | — | — | 4,562 | — | — | 4,562 |
| Unrealized losses on marketable securities | — | — | — | — | — | — | — | — | — | (41) | — | (41) |
| Net loss | — | — | — | — | — | — | — | — | — | — | (83,724) | (83,724) |
| Balances as of December 31, 2024 | — | — | — | — | 137,138 | $2,931 | 37,440,510 | $37 | $463,018 | $(41) | $(83,724) | $382,221 |
Item 8. Financial Statements and Supplementary
FAQ
- What is Oruka Therapeutics, Inc.'s issuance of warrants?
- Oruka Therapeutics, Inc. (ORKA) reported issuance of warrants of $2.52M in Q4 2025.
- How has Oruka Therapeutics, Inc.'s issuance of warrants changed year-over-year?
- Oruka Therapeutics, Inc.'s issuance of warrants decreased by 75.7% year-over-year, from $10.36M to $2.52M.
- What does issuance of warrants mean?
- Represents the accounting adjustments made to additional paid-in capital related to the issuance of warrants. This captures the equity component of financing arrangements that include derivative features.
Ask your AI about Oruka Therapeutics, Inc.'s issuance of warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude